Research Article| Volume 163, ISSUE 3, P490-497, December 2021

Download started.


Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

Published:September 30, 2021DOI:


      • Patients with recurrent ovarian cancer (OC) who responded to rucaparib treatment in Study 10 and ARIEL2 were characterized.
      • Duration of response (DOR) was used to group long- (≥1 y), intermediate- (6 mo to <1 y), and short-term responders (<6 mo).
      • The majority of long- and intermediate-term responders with BRCA wild-type OC had high genome-wide loss of heterozygosity.
      • BRCA structural variants were common in long-term responders and associated with longer DOR than other alteration types.
      • Our analyses show that reversion-resistant BRCA structural variants contribute to extended DOR to PARP inhibitor therapy.



      To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib.


      This post hoc analysis pooled patients from Study 10 (NCT01482715; Parts 2A and 2B; n = 54) and ARIEL2 (NCT01891344; Parts 1 and 2; n = 491). Patients with investigator-assessed complete or partial response per RECIST were classified based on duration of response (DOR): long (≥1 year), intermediate (6 months to <1 year), or short (<6 months). Next-generation sequencing was used to detect deleterious mutations and loss of heterozygosity (LOH) in tumors.


      Overall, 25.3% (138/545) of enrolled patients were responders. Of these, 27.5% (38/138) had long-term responses; 28.3% (39/138) were intermediate- and 34.8% (48/138) were short-term responders. Most of the long-term responders harbored a BRCA1 or BRCA2 (BRCA) mutation (71.1%, 27/38), and BRCA structural variants were most frequent among long-term responders (14.8%; 4/27). Responders with HGOC harboring a BRCA structural variant (n = 5) had significantly longer DOR than patients with other mutation types (n = 81; median not reached vs 0.62 years; HR, 0.21; 95% CI, 0.10–0.43; unadjusted p = 0.014). Among responders with BRCA wild-type HGOC, most long- and intermediate-term responders had high genome-wide LOH: 81.8% (9/11) and 76.9% (10/13), respectively, including 7 with deleterious RAD51C, RAD51D, or CDK12 mutations.


      Among patients who responded to rucaparib, a substantial proportion achieved responses lasting ≥1 year. These analyses demonstrate the relationship between DOR to PARP inhibitor treatment and molecular characteristics in HGOC, such as presence of reversion-resistant BRCA structural variants.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bryant H.E.
        • Schultz N.
        • Thomas H.D.
        • Parker K.M.
        • Flower D.
        • Lopez E.
        • et al.
        Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
        Nature. 2005; 434: 913-917
        • Farmer H.
        • McCabe N.
        • Lord C.J.
        • Tutt A.N.J.
        • Johnson D.A.
        • Richardson T.B.
        • et al.
        Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
        Nature. 2005; 434: 917-921
        • Kristeleit R.S.
        • Oaknin A.
        • Ray-Coquard I.
        • Leary A.
        • Balmana J.
        • Drew Y.
        • et al.
        Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
        Int. J. Gynecol. Cancer. 2019; 29: 1396-1404
        • Oza A.M.
        • Tinker A.V.
        • Oaknin A.
        • Shapira-Frommer R.
        • McNeish I.A.
        • Swisher E.M.
        • et al.
        Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from study 10 and ARIEL2.
        Gynecol. Oncol. 2017; 147: 267-275
        • Swisher E.M.
        • Lin K.K.
        • Oza A.M.
        • Scott C.L.
        • Giordano H.
        • Sun J.
        • et al.
        Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial.
        Lancet Oncol. 2017; 18: 75-87
        • Kristeleit R.
        • Shapiro G.I.
        • Burris H.A.
        • Oza A.M.
        • LoRusso P.
        • Patel M.R.
        • et al.
        A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors.
        Clin. Cancer Res. 2017; 23: 4095-4106
        • Swisher E.M.
        • Kwan T.T.
        • Oza A.M.
        • Tinker A.V.
        • Ray-Coquard I.
        • Oaknin A.
        • et al.
        Molecular and clinical determinants of response and resistance to the PARP inhibitor rucaparib for recurrent ovarian cancer treatment in ARIEL2 (parts 1 and 2).
        Nat. Commun. 2021; 12: 2487
        • Coleman R.L.
        • Oza A.M.
        • Lorusso D.
        • Aghajanian C.
        • Oaknin A.
        • Dean A.
        • et al.
        Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2017; 390: 1949-1961
        • del Campo J.M.
        • Matulonis U.A.
        • Malander S.
        • Provencher D.
        • Mahner S.
        • Follana P.
        • et al.
        Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial.
        J. Clin. Oncol. 2019; 37: 2968-2973
        • Ledermann J.A.
        • Harter P.
        • Gourley C.
        • Friedlander M.
        • Vergote I.
        • Rustin G.
        • et al.
        Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
        Lancet Oncol. 2016; 17: 1579-1589
        • Rafii S.
        • Gourley C.
        • Kumar R.
        • Geuna E.
        • Ern Ang J.
        • Rye T.
        • et al.
        Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
        Oncotarget. 2017; 8: 47154-47160
        • Lheureux S.
        • Lai Z.
        • Dougherty B.A.
        • Runswick S.
        • Hodgson D.R.
        • Timms K.M.
        • et al.
        Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization.
        Clin. Cancer Res. 2017; 23: 4086-4094
        • Lin K.K.
        • Harrell M.I.
        • Oza A.M.
        • Oaknin A.
        • Ray-Coquard I.
        • Tinker A.V.
        • et al.
        BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma.
        Cancer Discov. 2019; 9: 210-219
        • Garsed D.W.
        • Alsop K.
        • Fereday S.
        • Emmanuel C.
        • Kennedy C.J.
        • Etemadmoghadam D.
        • et al.
        Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer.
        Clin. Cancer Res. 2018; 24: 569-580
        • Kondrashova O.
        • Nguyen M.
        • Shield-Artin K.
        • Tinker A.V.
        • Teng N.N.H.
        • Harrell M.I.
        • et al.
        Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma.
        Cancer Discov. 2017; 7: 984-998
        • Patch A.-M.
        • Christie E.L.
        • Etemadmoghadam D.
        • Garsed D.W.
        • George J.
        • Fereday S.
        • et al.
        Whole–genome characterization of chemoresistant ovarian cancer.
        Nature. 2015; 521: 489-494
        • Watkins J.A.
        • Irshad S.
        • Grigoriadis A.
        • Tutt A.N.
        Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
        Breast Cancer Res. 2014; 16: 211
        • National Cancer Institute
        NCI Term Browser.
        CTCAE, 2017 (Accessed date: January 26, 2021)
        • Walsh T.
        • Lee M.K.
        • Casadei S.
        • Thornton A.M.
        • Stray S.M.
        • Pennil C.
        • et al.
        Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.
        Proc. Natl. Acad. Sci. U. S. A. 2010; 107: 12629-12633
        • Kondrashova O.
        • Topp M.
        • Nesic K.
        • Lieschke E.
        • Ho G.Y.
        • Harrell M.I.
        • et al.
        Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
        Nat. Commun. 2018; 9: 3970
        • Sun J.X.
        • He Y.
        • Sanford E.
        • Montesion M.
        • Frampton G.M.
        • Vignot S.
        • et al.
        A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
        PLoS Comput. Biol. 2018; 14e1005965
        • Randall M.
        • Burgess K.
        • Buckingham L.
        • Usha L.
        Exceptional response to olaparib in a patient with recurrent ovarian cancer and an entire BRCA1 germline gene deletion.
        J. Natl. Compr. Cancer Netw. 2020; 18: 223-228
        • Lee E.K.
        • Matulonis U.A.
        PARP inhibitor resistance mechanisms and implications for post-progression combination therapies.
        Cancers. 2020; 12: 2054